Newsroom | 22130 results

DUBLIN--(BUSINESS WIRE)--The "Vaccine Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of 818 vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. Fully revised and updated, the report provides details of vaccine deals from 2016 to 2025. Vaccine Collaboration and Li...

GOLDEN, Colo.--(BUSINESS WIRE)--Agreement with Immuno Cure adds to PharmaJet's portfolio of global development partnerships with innovative oncology & infectious disease developers....

ROME--(BUSINESS WIRE)--Can electromagnetic waves neutralize respiratory viruses? The answer is yes: on the stage of the Japan Health fair, from 25th to 27th June, e4life, the Italian company active in the biodefense industry, will be among the leading players presenting its innovative devices which use electromagnetic waves to render harmless respiratory viruses present in the air (transported via bioaerosol). This solution is a world first, with efficacy of over 90% and an almost instantaneous...

LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead’s Greed Kills Promise of Lenacapavir for HIV Prevention...

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with the filing of the def...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang’s resignation was due to increased professional commitments an...

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company’s governance framework. Currently, a dissenting investor group led by Advantech/Prime Success and Vivo Capital (together known as the “Dissenting Investor Group”) and certain former illegitimate board (the “...

DUBLIN--(BUSINESS WIRE)--The "Infectious Vaccine Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of 543 infectious vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual infectious vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the S...

TAMPA, Fla.--(BUSINESS WIRE)--In a major step toward HIV prevention, CAN Community Health, the nation’s leading resource in ending epidemics, launched an innovative same-day injectable PrEP (Pre-Exposure Prophylaxis) model, revolutionizing access to HIV prevention by offering long-acting injectable medication on the same day of initiation consultation. “This innovative program significantly reduces the barriers to HIV prevention by streamlining the process from consultation to administration,”...

EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2025. Summary of Results of Operations – Fiscal Third Quarter Net product sales were $489,000 and $440,000 for the fiscal third quarter ended April 30, 2025 and 2024, respectively. The increase of $49,000 was attributable to increased s...